Sartorius AG
XETRA: SRT.DE
Stock price
195 EUR
(+Infinity%) NaN day
Financial Performance
5Y price score: (80)
The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.
A score of 100 indicates that the stock did as well as the S&P 500 Index.
A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.
10Y return: 184.7%
EUR Per
Share
By default your notes are visible only to you.
145.4
52-week range
208.0
Your model inputs
Your fair value & Margin of safety
To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.
Forecast:
Valuation
Free Cash Flow Yield
2 %
Dividend Yield TTM
0.3 %
Market cap
16,946
Price / Earnings TTM
83
Price / Book TTM
6.2
PEG TTM
1
Earnings growth and return
LTM
5YR
10YR
Total return (price & dividends)
15.8 %
(57.3) %
184.7 %
Free cash flow per share growth
(62.2) %
(21.8) %
1,418.5 %
Earnings per share growth
83.6 %
(52.3) %
21.1 %
Founded: 1,870
Employees: 13,762
Business Summary:
Latest Earnings Call Takeaways
2025 Q4 (Feb 3, 2026)
1) Strategy & Leadership - CEO Michael Grosse expressed gratitude for the team's dedication and highlighted a smooth transition into his role. - The company focused on operational management amidst a challenging environment, achieving improved financial performance. - Sartorius aims for sustainable innovation-led growth, emphasizing investments in R&D and production capacity.
2) Financial & Segment Results - Full-year sales revenue increased by 7.6% in constant currencies, reaching slightly over EUR 3.5 billion. - Underlying EBITDA rose by 11.2% to EUR 1.052 billion, with a margin of 29.7%. - Bioprocess Solutions saw 9.5% growth in sales, driven by mid-teens growth in consumables, while Lab Products & Services remained flat at 0.2% growth. - The Americas and APAC regions both grew by 8.9%, with EMEA showing almost 6% growth.
| Metric | 2025 Results |
|---|---|
| Sales Revenue | EUR 3.5 billion |
| Underlying EBITDA | EUR 1.052 billion |
| EBITDA Margin | 29.7% |
| Bioprocess Solutions Growth | 9.5% |
| Lab Products Growth | 0.2% |
3) Problems / Headwinds - Equipment sales continued to be soft, although stabilizing in H2 2025. - The company faced headwinds from U.S. dollar weakness and tariffs, impacting reported sales growth. - The ongoing cautious investment activities from core customers contributed to a challenging market environment.
4) Operational or Product Plans - Sartorius launched several new products, including a PFAS-free filtration solution and a continuous bioprocessing platform. - The company completed expansions in Aubagne and Germany and is constructing a new site in South Korea to enhance manufacturing capabilities. - The acquisition of MATTEK is expected to contribute positively to growth, particularly in advanced 3D cell models.
5) Guidance & Outlook / Investor Angle - For 2026, Sartorius expects sales growth of 5% to 9% and an underlying EBITDA margin slightly above 30%. - The guidance reflects cautious optimism, with expectations for continued growth in Bioprocess Solutions and stabilization in Lab Products & Services. - The company anticipates that equipment sales will remain stable, with growth in consumables expected to be in the low teens, excluding China.
Bottom line: Sartorius demonstrated strong operational performance in 2025, positioning itself for sustainable growth in 2026 despite ongoing market challenges. The company’s focus on innovation and strategic investments, coupled with a solid order book, supports a positive outlook for shareholders.
Sartorius AG — Financial Overview, Stock Price, Market Cap
Sartorius AG is a company. Founded in 1870. As of July 20, 2026, the company's market capitalization is $16945649955 with a current stock price of $195.00.